SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Fairchild who wrote (75)11/3/1998 9:02:00 PM
From: burner  Read Replies (1) of 134
 
Primate study nears completion

Immune Network Research Ltd IMM
Shares issued 19,970,452 Nov 3 close $0.20
Tue 3 Nov 98 News Release
Mr. Victor Jones reports
The blood plasma and tissue sampling has been completed on its phase II
primate study of its proprietary monoclonal antibody 1F7. The study of the
effects of mAb 1F7 on the immune system of macaques infected with a simian
form of HIV follows on from an earlier study in macaques which showed
beneficial effects of mAb 1F7. In that study mAb 1F7 appeared to increase
the breadth and potency of the immune response, increase virus neutralizing
antibodies and normalize the immune response against the SHIV viral
infection. The macaque monkey is a preferred animal model for the study of
HIV disease in humans.
Arrangements have been made to analyze all of the plasma samples taken over
the six month term of the macaque study using specialized equipment for low
threshold detection of SHIV virus (viral load) and other measures of immune
response to determine whether mAb 1F7 promotes restoration of an already
impaired immune system. The study included a second series of injections of
mAb 1F7 which may yield valuable data on repeated use of mAb 1F7 and
characterization of mAb 1F7. A study of the effects of mAb 1F7 on the lymph
nodes is also under way in collaboration with a university researcher. All
animals survived the study and continue to be under close observation as
part of related work by researchers at Harvard University. Certain animals
may be used in further research in support of the application for the human
clinical trial of mAb 1F7 under an investigational new drug protocol.
The study is under direction of Dr. Sybille Muller of Immpheron, Inc., the
company's partner on the mAb 1F7 project. Dr. Muller published results of
the earlier study in the prestigious Proceedings of the National Academy of
Science USA (PNAS Vol. 95 pp. 276-281, Jan. 6, 1998). Results of the just
completed study are anticipated in the next few weeks and will similarly be
prepared for publication. Planning for further research and the initial
human clinical trial is under way.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News